Managing Steroid Increase in PMR Patients

Approach to Steroid Increase for Relapse

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) recommend returning to the pre-relapse dose that previously controlled symptoms effectively, typically the last dose where the patient was symptom-free 2, 1
If uncertain about the previous effective dose, increasing to 5 mg daily is a reasonable starting point for patients relapsing at very low doses 1
Once symptoms are controlled, gradually reducing the dose over 4-8 weeks back to 2.5 mg is recommended 2, 1
After reaching 2.5 mg again, tapering more slowly than before, reducing by only 1 mg every 4 weeks, is advised 2, 3

The American College of Rheumatology (ACR) and EULAR suggest that PMR requires adequate glucocorticoid dosing to control inflammation, and undertreating leads to prolonged disease activity and potentially higher cumulative steroid exposure 2, 4
Initial doses ≤7.5 mg/day are discouraged as they provide insufficient anti-inflammatory effect 4
A brief increase to 5-7.5 mg is far safer than the initial treatment range of 12.5-25 mg daily 4
For patients with a history of gout, adequate PMR control actually reduces overall inflammatory burden, and short-term modest prednisone increases (5-7.5 mg) are unlikely to trigger gout flares 2

The Annals of the Rheumatic Diseases recommend scheduling follow-up every 4 weeks during the adjustment period to assess clinical symptoms, inflammatory markers, and monitor for steroid-related adverse effects 2, 3
Assessing clinical symptoms, such as shoulder/hip girdle pain and morning stiffness duration, is crucial 3
Checking inflammatory markers (ESR/CRP) to confirm disease control is also important 3
Monitoring for steroid-related adverse effects, such as blood glucose, blood pressure, and bone health, is necessary 2

The American College of Rheumatology (ACR) recommends adding methotrexate 7.5-10 mg weekly to allow lower prednisone doses, especially for patients with frequent relapses or those at high risk for glucocorticoid adverse events 2, 3
Methotrexate is specifically indicated for patients with frequent relapses, prolonged therapy requirements, or those at high risk for glucocorticoid adverse events 2, 3

The European League Against Rheumatism (EULAR) recommends physical therapy for maintaining muscle mass and function 2
Tramadol is reasonable for additional pain control, as it addresses pain without interfering with PMR treatment 2
NSAIDs should not replace glucocorticoids for PMR treatment, as they only provide symptomatic relief without addressing underlying inflammation 2, 4